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Acrylamide is an environmental and industrial 
chemical. People are exposed to this chemical 
through its formation in foods during heat­
ing (Dybing et al. 2005; Mottram et al. 2002; 
Stadler et al. 2002), tobacco smoke (Smith et al. 
2000), and occupational activities involving the 
production and use of acrylamide (Hagmar 
et al. 2005; Jones et al. 2006; Paulsson et al. 
2006). The health effects of acrylamide have 
been reviewed extensively in the literature 
(Exon 2006; Klaunig 2008; LoPachin et al. 
2008; Shipp et al. 2006). Acrylamide can be 
neurotoxic in humans and animals and carci­
nogenic in animals, and has been categorized 
as a suspected human carcinogen [Hagmar 
et al. 2001; International Agency for Research 
on Cancer (IARC) 1995; Manjanatha et al. 
2006]. It is also a reproductive and develop­
mental toxicant in male rats and mice [National 
Toxicology Program (NTP) 2004]. The lifelong 
exposure of most of the population to acrylam­
ide through food and smoking has raised con­
cerns about its potential health effects at these 
low levels of intake. To aid in the assessment 
of possible health risks, the extent of the actual 
acrylamide exposure in the general population 
needs to be characterized. 
Acrylamide is metabolized to glycid­
amide by cytochrome P450 2E1 (CYP2E1). 
Glycidamide forms DNA adducts (Gamboa 
da Costa et al. 2003) and is assumed to be the 
agent responsible for causing the toxicologicl 
effects. Recent studies using CYP2E1 knock­
out mice have confirmed glycidamide as the 
actual genotoxic and reproductive toxic agent 
(Ghanayem et al. 2005a, 2005b). CYP2E1 
is regulated at the transcriptional, transla­
tional, and posttranslational level (Ingelman­
Sundberg et al. 1994) and affected by genetic 
polymorphisms (Itoga et al. 2002; McCarver 
et al. 1998). The glycidamide­to­acrylamide 
ratio, which can be used as an indicator of the 
extent of acrylamide metabolism by CYP2E1, 
was found to be highly variable between indi­
viduals (Bjellaas et al. 2007; Hartmann et al. 
2008 Schettgen et al. 2004; Vesper et al. 
2007, 2008), indicating that interindividual 
differences may be a factor in susceptibility to 
toxic effects. This high variability makes the 
prediction of glycidamide exposure based on 
acrylamide exposure difficult, and it creates 
the need for measuring glycidamide exposure 
as well as acrylamide exposure.
Hemoglobin adducts of   acrylamide 
(HbAA) and glycidamide (HbGA) are 
well­established biomarkers of exposure to 
these chemicals (Dybing et al. 2005; Ogawa 
et al. 2006). The adducts are formed in a 
dose­dependent manner as shown in   animal 
and human studies (Fennell et al. 2005; 
Tareke et al. 2006), with occupational expo­
sures (Jones et al. 2006; Schettgen et al. 
2004), with tobacco use (Kütting et al. 2008; 
Scherer et al. 2007; Schettgen et al. 2004; 
Vesper et al. 2008), and with food con­
sumption (Hagmar et al. 2005; Wilson et al. 
2008). The use of these hemoglobin adducts 
for exposure assessments is analogous to the 
use of glycated hemoglobin to monitor blood 
glucose levels in diabetic patients (Osterman­
Golkar and Vesper 2006). HbAA and HbGA 
are stable over the life span of the erythro­
cytes, and they therefore offer a measure of 
cumulative internal exposure over a period of 
120 days (Fennell et al. 1992).
To date, no data on internal acrylamide 
and glycidamide exposure acquired by use of 
HbAA and HbGA in the general U.S. popu­
lation are available to aid in the assessment of 
health risks associated with this exposure. The 
aim of this study was to determine human 
exposure to acrylamide and its primary 
metabolite glycidamide in a representative 
subset of the general U.S. population. 
Materials and Methods
Specimens were obtained from participants 
of the 2003–2004 cycle of the National 
Health and Nutrition Examination Survey 
(NHANES), a nationally representative 
survey of the noninstitutionalized civilian 
population of the United States. NHANES 
obtained a stratified, multistage probability 
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Ba c k g r o u n d: The lifelong exposure of the population to acrylamide has raised concerns about the 
possible health effects of the chemical. Data on the extent of exposure to acrylamide and its primary 
metabolite, glycidamide, are needed to aid in the assessment of potential health effects. 
oBjectives: The aim of this study was to assess human exposure to acrylamide and glycidamide 
in the general U.S. population through the measurement of hemoglobin adducts of acrylamide 
(HbAA) and glycidamide (HbGA).
Me t h o d s : HbAA and HbGA were measured in 7,166 subjects from the National Health and 
Nutrition Examination Survey. Stratified HbAA and HbGA data were reported by sex, age groups, 
race/ethnicity (Mexican American, non-Hispanic black, non-Hispanic white), and smoking status 
based on serum cotinine levels. Covariate-adjusted geometric means for each demographic group 
were calculated using multiple regression analysis.
re s u l t s: HbAA and HbGA levels ranged from 3 to 910 and from 4 to 756 pmol/g hemoglobin, 
respectively, with smokers having the highest levels overall. Tobacco smoke exposure in non  smokers 
had a small but significant effect on HbAA and HbGA levels. Adjusted geometric mean levels for 
children 3–11 years of age were higher than for adults ≥ 60 years of age [mean (95% confidence 
interval): HbAA, 54.5 (49.1–51.5) and HbGA, 73.9 (71.3–76.6) vs. HbAA, 46.2 (44.3–48.2) and 
HbGA, 41.8 (38.7–45.2)]. Levels were highest in Mexican Americans [HbAA: 54.8 (51.9–57.8), 
HbGA: 57.9 (53.7–62.5)], whereas non-Hispanic blacks had the lowest HbGA levels [43.5 
(41.1–45.9)]. 
co n c l u s i o n s: U.S. population levels of acrylamide and glycidamide adducts are described. The 
high variability among individuals but modest differences between population subgroups suggest 
that sex, age, and race/ethnicity do not strongly affect acrylamide exposure. Adduct concentration 
data can be used to estimate relative exposure and to validate intake estimates.
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cluster sample designed to represent the U.S. 
population on the basis of age, sex, and race/
ethnicity. Certain subpopulations were over­
sampled to allow for more precise estimates. 
All participants in the survey gave written 
informed consent. Information on NHANES 
procedures may be found at the Centers for 
Disease Control and Prevention Web site 
(CDC 2009). The NHANES protocol for 
each survey period was reviewed and approved 
by the National Center for Health Statistics 
Institutional Review Board. 
A total of 7,166 whole­blood samples 
from individuals ≥ 3 years of age were used 
in this study. Collection was performed 
by antecubital phlebotomy into EDTA­
containing vacutainers and stored at –70°C 
before analysis. HbAA and HbGA were meas­
ured in 350 µL whole blood and analyzed by 
high­performance liquid chromatography/ 
tandem mass spectrometry (HPLC/MS/MS), 
as described previously (Vesper et al. 2007, 
2008). In brief, the adducts of acrylamide 
and glycidamide at the N­terminal valines 
of hemoglobin were cleaved from the pro­
tein chain by use of modified Edman reaction 
with pentafluorophenyl isothiocyanate as the 
Edman reagent (Mowrer et al. 1986). The 
resulting pentafluoro  phenylthiohydantoin 
reaction products were extracted by use of liq­
uid–liquid extraction and analyzed by HPLC/
MS/MS. Calibrators, reagent blanks, and 
quality­control materials were processed in 
the same manner as the samples. Hemoglobin 
adduct concentrations are reported relative 
to the amount of hemoglobin used in the 
analysis. The total hemoglobin content was 
determined as cyanomethhemoglobin by use 
of a commercial assay (Stanbio Laboratory, 
Boerne TX). The detection limits for HbAA 
and HbGA adducts were 3 and 4 pmol/g 
hemoglobin, respectively. The interday impre­
cision (n = 20 days) of this method, expressed 
as percentage coefficient of variation, were 
13% for HbAA and 19% for HbGA, on 
average, determined with three blood pools 
[HbAA and HbGA concentrations in pico­
moles per gram hemoglobin: pool 1 (135 
and 93); pool 2 (103 and 700); pool 3 (62 
and 50), respectively. Calibrators were syn­
thesized by Bachem (King of Prussia, PA) 
from octapeptides with the same amino acid 
sequence as the N­terminus of the β­chain 
of hemoglobin reacted with acrylamide and 
glycidamide at the valine (AA­octapeptide: 
96% purity by HPLC/UV and MALDI 
(matrix­assisted laser desorption/ionization)/
MS; and GA­octapeptide: 90% purity by 
HPLC/UV and MALDI/MS). Calibrators 
were verified for accuracy in­house by 
HPLC/MS and by the U.S. Food and Drug 
Administration (FDA)/National Center for 
Toxicology Research by use of HPLC/MS 
and that organization’s own standards. The 
corresponding stable isotope­labeled com­
pounds [AA­octapeptide and GA­octapeptide 
with stable­isotope labeled valine (13C515N)] 
were synthesized by the same company 
and used as internal standards. The Edman 
reagent was obtained from Fluka (St. Louis, 
MO), and formamide was obtained from 
USB Corporation (Cleveland, OH). All other 
reagents were purchased from Fisher Scientific 
(Fair Lawn, NJ).
HbAA, HbGA, and cotinine levels were 
log10­transformed for statistical analysis, 
because the data distribution is skewed to the 
higher levels. For selected age groups, sexes, 
and three race/ethnicity groups, we calculated 
the geometric means and distribution percen­
tiles for HbAA and HbGA, the HbGA:HbAA­
ratio, and the sum of HbAA and HbGA. Race/
ethnicities were self­reported as non­  Hispanic 
black, non­Hispanic white, and Mexican 
American. Individuals not included in one 
of these three race/ethnicity groups were 
included in the total population estimates. 
Geometric means and percentiles were calcu­
lated with SUDAAN version 9.0 (Research 
Triangle Institute, Research Triangle Park, 
NC). SUDAAN uses sample weights and cal­
culates variance estimates that account for the 
complex survey design. We estimated 95% 
confidence intervals (CIs) for geometric means 
were estimated on the basis of the Taylor series 
linearization method (Shah et al. 1996), and 
adapted CIs for percentiles from the methods 
of Korn and Graubard (1998) and Woodruff 
(1952). For concentrations below the limit of 
detection (LOD), a level equal to the LOD 
divided by the square root of 2 was used 
(Hornung and Reed 1990). Because of the 
known effect of smoking on acrylamide levels, 
we divided the data into two groups according 
to cotinine levels (serum cotinine ≤ 10 ng/mL: 
nonsmoker group; serum cotinine >10 ng/mL: 
smoker group) (Pirkle et al. 2006). 
We calculated covariate­adjusted geomet­
ric means for selected demographic groups 
separately for the nonsmoking and smok­
ing populations, using least­squares mul­
tiple regression adjusted for the covariates 
of age group (3–11, 12–19, 20–39, 40–59, 
≥ 60 years), sex (male and female), and self­
reported race/ethnicity (non­Hispanic white, 
non­Hispanic black, and Mexican American), 
and the continuous covariates of body sur­
face area (BSA) and the base 10 logarithm 
of serum cotinine. We used BSA to adjust 
for blood volume and thus to account for 
other possible variability affecting delivery 
of acrylamide to the blood related to body 
size measures and was calculated according to 
Mosteller (1987). To arrive at the final model, 
we used backward elimination with SUDAAN 
to eliminate the nonsignificant interactions 
(p > 0.05) one at a time and then the non­
significant main effects. Nonsignificant main 
effects were kept in the model as confound­
ers when they changed the beta coefficients 
for significant main effects or interactions by 
> 10%. Once the backward procedure was 
completed, main effects and interactions were 
added back into the model one at a time and 
kept in the final model when they were sig­
nificant (p < 0.05). Hypothesis tests to com­
pare covariate­adjusted geometric means were 
performed using the Contrast option in the 
Regress procedure of SUDAAN. For further 
details about the final model and observed 
interactions between the investigated vari­
ables, see Supplemental Material, Model 
Information, available online (doi:10.1289/
ehp.0901021.S1 via http://dx.doi.org).
Results
HbAA and HbGA levels were detectable in 
99.9% and 97.5% of all samples, respec­
tively, with individual levels ranging from < 3 
to 910 pmol/g hemoglobin for HbAA and 
< 4 to 756 pmol/g hemoglobin for HbGA. 
Distributions were different in nonsmokers 
and smokers (Figure 1). Geometric mean 
HbAA levels were 49.1–72.5 pmol/g hemo­
globin higher in smokers than in nonsmokers 
when compared across subgroups of sex, age, 
or race/ethnicity (Table 1); HbGA levels were 
31.6–52.2 pmol/g hemoglobin higher. Ratios 
of HbGA:HbAA ranged from 0.08 to 0.25 
units lower in smokers than in nonsmokers 
when compared across subgroups of sex, age, 
and race/ethnicity. The intersubject variability 
(difference between 90th and 10th percentile) 
for HbAA and HbGA in nonsmokers was 
45 pmol/g hemoglobin and 66 pmol/g hemo­
globin, respectively [Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901021.S1)]. In 
smokers, it was much larger, with 179 pmol/g 
hemoglobin and 191 pmol/g Hb, for HbAA 
and HbGA, respectively (Supplemental 
Material, Table 2). The subgroups of sex, age, 
and race/ethnicity showed similar intersubject 
variability as the entire group of either smok­
ers or nonsmokers (Supplemental Material, 
Figures 1 and 2). 
Nonsmokers. In nonsmokers (Table 2), 
the covariate­adjusted geometric mean HbAA 
and HbGA levels were highest in children 
3–11 years of age [mean, 54.5 (95% CI, 
52.4–56.8) pmol/g hemoglobin for HbAA, 
73.9 (95% CI, 71.3–76.6) pmol/g hemoglobin 
for HbGA] and lowest in adults age ≥ 60 years 
[46.2 (95% CI, 44.3–48.2) pmol/g hemo­
globin for HbAA, 41.8 (95% CI, 38.7–45.2) 
pmol/g hemoglobin for HbGA]. Among the 
race/ethnic groups, Mexican Americans had 
the highest HbAA [54.8 (95% CI, 51.9–57.8) 
pmol/g Hb] and HbGA levels [57.9 (95% 
CI, 53.7–62.5) pmol/g Hb]. HbGA lev­
els were higher in men than in women and 
lowest in non­Hispanic blacks [43.5 (95% 
CI, 41.1–45.9) pmol/g Hb] compared Vesper et al.
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with non­Hispanic whites [52.6 (95% CI, 
50.3–54.9) pmol/g Hb] and MA [57.9 (95% 
CI, 53.7–62.5) pmol/g Hb]. 
The HbGA:HbAA ratios were influenced 
by the variables of age, sex, race/ethnicity, 
cotinine and BSA. Several interactions were 
observed between these variables. Therefore 
covariate­adjusted geometric mean values were 
calculated for each age group and certain per­
centiles of cotinine levels by race/ethnic group 
[Supplemental Material, Table 3 (doi:10.1289/
ehp.0901021.S1)] and for certain percentiles 
of BSA separate for each sex (Supplemental 
Material, Table 4). The ratios decreased with 
increasing age in all race/ethnic groups, with 
levels in the ≥ 60 years group [0.74 (95% CI, 
0.63–0.87), 0.63 (95% CI, 0.51–0.79), 0.79 
(95% CI, 0.69–0.90) in non­Hispanic whites, 
non­Hispanic blacks, and Mexican Americans, 
respectively] being approximately half of the 
levels in the 5–9 years group. Non­Hispanic 
blacks had the lowest ratios across all age 
groups and across all percentiles of cotinine. 
The relationship between non­Hispanic blacks 
and cotinine appears stronger than for the 
other race/ethnic groups. Women had higher 
ratios than men across all percentiles of BSA 
[1.05 (95% CI, 1.00–1.11) in women, 0.92 
(0.87–0.97) in men, at the 75th percentile of 
BSA each]. The ratios decreased modestly with 
increasing BSA in both men and women. 
Cotinine levels ranged in the nonsmoker 
population from 0.01 to 10 ng/mL. The esti­
mated slope for the effect of the logarithm of 
cotinine levels on HbAA levels was 0.0238 
(p = 0.0002) and on HbGA levels was 
0.0228 (p = 0.0223), indicating that a 10% 
increase in serum cotinine would be associ­
ated with a 0.23% (95% CI, 0.10–0.35%) 
increase in HbAA levels and a 0.22% (95% 
CI, 0.03–0.41%) increase in HbGA   levels. 
Simulating an increase in cotinine   levels 
from a level equal to the first quartile 
(0.018 ng/mL) up to a level equal to the third 
quartile (0.270 ng/mL) would correspond to 
a 32% increase in HbAA and HbGA levels 
(assuming a starting point at the 10th percen­
tile). The estimated slope for the effect of BSA 
in the HbAA model was –0.0399 (p < 0.0001), 
indicating that an increase in BSA from the 
median BSA (1.75 m2) to the 75th percentile 
of BSA (1.97 m2) would be associated with 
a 2.00% (95% CI, 1.04–2.95%) decrease in 
HbAA levels. 
Smokers. In smokers, HbAA and HbGA 
values were influenced by the variables race/
ethnicity, BSA, age, cotinine, and sex. Several 
interactions were found between these vari­
ables. Therefore, covariate­adjusted geometric 
mean HbAA levels were calculated for each 
race/ethnic group and certain percentiles of 
BSA levels by sex, and the HbGA:HbAA 
ratio for certain levels of cotinine by sex 
[Supplemental Material, Table 5 (doi:10.1289/
ehp.0901021.S1)]. HbAA, HbGA, and the 
HbAA:HbGA ratios were calculated for spe­
cific ages (20, 40, and 60 years) separately 
for each race/ethnic group (Supplemental 
Material, Table 6). Similar to nonsmokers, 
Figure 1. Frequency distribution of HbAA (A) and HbGA (B) in nonsmokers and smokers. Hb, hemoglobin.
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Table 1. Geometric mean (95% CI) (pmol/g hemoglobin) and sample size of HbAA, HbGA, and the HbGA:HbAA ratio by sex, age, race/ethnicity, and smoking 
  status in the general U.S. population. 
Nonsmokers Smokers
  HbAA HbGA HbGA:HbAA ratio HbAA HbGA HbGA:HbAA ratio 
Group GM (95% CI) No. GM (95% CI) No. GM (95% CI) No. GM (95% CI) No. GM (95% CI) No. GM (95% CI) No.
All 50.0 (48.5–51.7)  5,686 51.1 (49.0–53.2)  5,809 1.01 (0.97–1.06)  5,464 113 (103–123)  1,316 93.5 (86.5–101)  1,357 0.82 (0.79–0.85)  1,282
Sex
Female 49.5 (48.2–50.8)  3,050 51.8 (49.1–54.7)  3,111 1.04 (0.99–1.09)  2,931 120 (108–133)  483 104 (94.9–115)  496 0.86 (0.82–0.90)  466
Male 50.7 (48.4–53.1)  2,636 50.2 (48.4–52.0)  2,698 0.98 (0.94–1.02)  2,533 108 (97.2–121)  833 87.2 (79.4–95.7)  861 0.80 (0.76–0.83)  816
Age group (years)
3–11 58.7 (56.2–61.2)  1,070 73.4 (70.5–76.4)  1,138 1.25 (1.20–1.30)  1,030 NDa NDa NDa
12–19 52.0 (50.1–54.0)  1,629 50.6 (46.7–54.7)  1,658 0.97 (0.89–1.05)  1,563 103 (88.1–119)  240 93.2 (80.4–108)  248 0.89 (0.85–0.93)  234
20–39 51.0 (48.5–53.8)  951 51.7 (48.4–55.3)  972 1.00 (0.95–1.06)  919 118 (106–131)  444 98.2 (88.5–109)  464 0.84 (0.80–0.88)  435
40–59 48.6 (46.1–51.2)  784 49.1 (47.0–51.2)  792 1.00 (0.95–1.06)  753 116 (106–127)  371 94.2 (87.1–102)  376 0.79 (0.75– 0.83)  362
≥ 60 44.4 (42.6–46.2)  1,252 41.0 (38.1–44.1)  1,249 0.92 (0.86–0.98)  1,199 93.5 (84.2–104)  252 77.2 (70.1–85.1)  258 0.81 (0.76–0.86)  243
Race/ ethnicity
NHW 50.1 (48.5–51.8)  2,254 51.6 (49.2–54.1)  2,287 1.02 (0.97–1.06)  2,172 114 (103–127)  698 97.8 (88.5–108)  714 0.84 (0.81–0.87)  682
NHB 50.5 (47.5–53.7)  1,480 46.3 (43.8–48.9)  1,533 0.91 (0.83–1.00)  1,405 123 (108–141)  361 82.1 (72.2–93.5)  381 0.66 (0.60–0.73)  350
MA 56.3 (53.2–59.6)  1,582 60.9 (56.8–65.3)  1,622 1.08 (1.01–1.15)  1,533 109 (98.5–120)  190 92.5 (79.7–107)  194 0.85 (0.77–0.94)  186
Abbreviations: GM, geometric mean; MA, Mexican American; ND, not determined; NHB, non-Hispanic black; NHW, non-Hispanic white. 
an < 10. Exposure of the U.S. population to acrylamide
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covariate­adjusted geometric HbGA levels were 
higher in females [108 (95% CI, 99.4–117)] 
than in males [87.9 (95% CI, 78.5–98.5)], 
whereas no difference was observed for HbAA 
levels. HbGA:HbAA ratios were higher in 
females than males across all percentiles of coti­
nine [1.59 (95% CI, 1.28–1.97) in women; 
0.87 (95% CI, 0.74–1.03) in men, at the 
90th percentile of cotinine each]. In addition, 
HbAA, HbGA levels, and the HbGA:HbAA 
ratios decreased with increasing age, except for 
Mexican Americans, where HbAA and HbGA 
levels remained constant. Non­Hispanic blacks 
had the lowest HbGA values at age groups 
40 years [83.4 (95% CI, 74.8–93.1) pmol/g 
hemoglobin] and 60 years [59.1 (95% CI, 
51.1–68.5) pmol/g hemoglobin] and the low­
est HbAA/HbGA ratios across all age groups 
[0.45 (95% CI, 0.36–0.56) at age 60]. In 
contrast to nonsmokers, the HbGA:HbAA 
ratios decreased with increasing cotinine levels. 
HbAA levels modestly increased with increas­
ing BSA in both females and males.
An increase in serum cotinine was associ­
ated with an increase in HbAA. This increase 
was highest at low BSA levels. A 10% increase 
in serum cotinine levels was associated with 
an increase in HbAA by 3.16% (95% CI, 
2.52–3.80), 2.47% (95% CI, 1.95–2.99) and 
1.93% (95% CI, 1.37–2.49) at the 25th, 50th, 
and 75th percentile of BSA, respectively. For 
HbGA, the estimated slope for the effect of the 
logarithm of cotinine levels was 0.1476 (p = 
0.0001), indicating that every 10% increase 
in serum cotinine was associated with a 1.41% 
(95% CI, 0.89–1.95) increase in HbGA. A 
10% increase in serum cotinine was associated 
with a decrease in the HbGA:HbAA ratio of 
1.1% (95% CI, –1.44 to 0.76) in women and 
a nonsignificant decrease of 0.25% (95% CI, 
–0.54 to 0.005) in men.
Relationship between HbAA and HbGA. 
The log­transformed HbAA and HbGA levels 
were linearly related (r2 = 0.4213, p < 0.0001). 
A multiple regression model for nonsmok­
ers that included sex, race/ethnicity, cotinine, 
and BSA as independent variables to predict 
HbGA levels based on HbAA levels showed a 
significant interaction between race/ethnicity 
and HbAA levels (p = 0.0133). In this model, a 
10% increase in HbAA was accompanied by a 
9.62% (95% CI, 8.92–10.35%), 7.55% (95% 
CI, 6.21–8.88%), and 9.65% (95% CI, 7.96–
11.36%) increase in HbGA for non­Hispanic 
whites, non­Hispanic blacks, and Mexican 
Americans, respectively. In a similar model for 
smokers, a 10% increase in HbAA was accom­
panied by an 8.62% increase in HbGA (no 
interactions between HbAA and the other vari­
ables were detected).
Discussion
Exposure to acrylamide, as indicated by the 
presence of HbAA or HbGA, was detectable 
in > 99% of all NHANES participants, indi­
cating that most of the U.S. population is 
exposed to this chemical. However, the levels 
of HbAA or HbGA were not profoundly dif­
ferent among several population subgroups 
but differed highly among individuals, sug­
gesting that individual exposures were affected 
mainly by factors other than age, sex, or race/
ethnicity. In addition, the relationship of levels 
of HbAA to HbGA could be useful in study­
ing factors related to the metabolic conversion 
of acrylamide to the more toxic glycidamide. 
The HbAA levels in children were mod­
estly higher than those in two older age 
groups, and the HbGA levels in children 
were higher than those in all four older age 
groups even after adjustment for body size, 
cotinine, and sex. The higher levels in chil­
dren may be due to the known larger intake 
of food per body mass in children, particularly 
acrylamide­rich foods such as french fries and 
potato chips, as suggested elsewhere (Dybing 
et al. 2005; Mucci and Wilson 2008). In addi­
tion, children have the highest HbGA:HbAA 
ratios, whereas adults ≥ 60 years of age have 
the lowest ratios. Smokers show similar pat­
terns, with biomarker values and ratios being 
higher at young age. This suggests differences 
in the acrylamide metabolism or metabolic 
rate in these age groups. The reasons for these 
different ratios are not fully understood. 
Metabolism and clearance of drugs are higher 
in children in part because of the larger liver­
to­body weight ratio and the higher blood 
flow through the liver compared with older 
adults, in whom liver volume and liver blood 
flow are decreased (Greim and Snyder 2008). 
Further investigation is needed to assess pos­
sible health effects associated with acrylamide 
exposure in children.
The observed differences in acrylam­
ide exposure between race/ethnic groups, 
with Mexican Americans having the highest 
HbAA and HbGA levels and non­Hispanic 
blacks having the lowest HbGA levels and 
HbGA:HbAA ratios in nonsmokers and 
smokers, have not been described before. The 
differences observed in nonsmokers could 
be explained by different food consumption 
patterns. The 2003–2004 U.S. Department 
of Agriculture (USDA) food consumption 
survey reported differences in food con­
sumption patterns for total sugars and car­
bohydrate­rich food among non­Hispanic 
whites, non­  Hispanic blacks, and Mexican 
Americans (USDA­ARS 2007), and this pat­
tern appears similar to the pattern observed 
for HbAA and HbGA. Carbohydrates are 
precursors for acrylamide formation during 
food processing (Mottram et al. 2002; Stadler 
et al. 2002). Thus, elevated consumption of 
carbohydrate­rich food in Mexican Americans 
may explain in part the elevated HbAA and 
HbGA levels in this group. The significantly 
lower HbGA:HbAA ratios and HbGA forma­
tion rate (per unit increase of HbAA) in non­
Hispanic blacks may indicate differences in 
polymorphisms of the genes for CYP2E1 or of 
the genes for glutathione S­transferase (GST), 
which are involved in phase II detoxification 
of acrylamide and glycidamide. Different fre­
quencies in polymorphisms in the genes for 
CYP2E1 in different race/ethnicity groups 
have been mentioned in literature (Bartsch 
et al. 2000; Bolt et al. 2003), and associations 
between polymorphisms in the genes for GST 
and the HbGA:HbAA ratio have been reported 
(Duale et al. 2009). Medications and alcohol 
are also metabolized by CYP2E1 and thus may 
affect CYP2E1 activity and metabolism of 
acrylamide to glycidamide. These factors could 
not be assessed in this study. Therefore, further 
studies are needed to better explain these differ­
ences in the observed HbGA:HbAA ratio. 
The ranges of HbAA and HbGA levels 
measured in this study are similar to those 
Table 2. Covariate-adjusted geometric mean estimates (95% CI) of HbAA, HbGA (pmol/g hemoglobin), and 
the HbGA:HbAA ratio in the nonsmoking U.S. population by sex, age, and race/ethnicity. 
Parameter Group  HbAA  HbGA HbGA:HbAA ratioa
Sex Male 51.7 (49.6–53.8) 50.1 (50.7–56.3) 0.97 (0.94–1.02)
Female 50.3 (49.1–51.5) 53.4 (48.2–52.1)b 1.07 (1.03–1.13)
Age group 3–11 54.5 (52.4–56.8)c 73.9 (71.3–76.6)d 1.62 (1.39–1.87)
12–19 51.8 (49.9–53.7) 51.9 (48.3–55.7) 1.42 (1.29–1.58)
20–39 52.8 (50.5–55.3) 52.7 (48.8–56.8) 1.16 (1.12–1.20)
40–59 50.7 (47.9–53.6) 50.0 (47.8–52.4) 0.86 (0.78–0.94)
≥ 60 46.2 (44.3–48.2)e 41.8 (38.7–45.2)d 0.63 (0.51–0.78)
Race/ethnicity NHW 50.7 (49.1–52.3) 52.6 (50.3–54.9)f 1.03 (0.98–1.07)
NHB 48.9 (46.14–51.84) 43.5 (41.1–45.9)g 0.90 (0.82–1.00)
MA 54.8 (51.9–57.8)h 57.9 (53.7–62.5) 1.06 (0.99–1.13)
Abbreviations: MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white. Variables used in the 
model: age group, sex, race/ethnicity log-converted cotinine levels, and BSA (except for the HbGA model). 
aBecause of significant race/ethnicity–cotinine and sex–BSA interactions, only the levels obtained at the 50th per-
centile of cotinine (for race/ethnicity levels) and of BSA (for sex levels) are shown. Similarly, for age groups, the levels 
at the median age for each age group (7 years for 3- to 11-year group, 15.5 years for 12- to 19-year group, 29.5 years 
for 20- to 39-year group, 49.5 years for 40- to 49-year group, 70 years for ≥ 60-year group) are shown. bDifferent from 
males (p < 0.004). cDifferent from 12- to 19-year group (p = 0.04), 40- to 59-year group (p = 0.03). dDifferent from all age 
groups (p < 0.0001). eDifferent from 3- to 11-year group, 12- to 19-year group, 20- to 39-year group, 40- to 59-year group 
(p < 0.0001 for all groups). fDifferent from MA (p = 0.004), NHB (p < 0.0001). gDifferent from MA (p < 0.0001). hDifferent 
from NHW (p < 0.008), NHB (p < 0.0001).Vesper et al.
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reported in other study populations (Bjellaas 
et al. 2007; Chevolleau et al. 2007; Hartmann 
et al. 2008; Heudorf et al. 2008; Kütting et al. 
2008; Olesen et al. 2008; Vesper et al. 2007, 
2008; Wilson et al. 2008; Wirfält et al. 2008). 
The mean and median levels reported in these 
study populations for nonsmokers differ, rang­
ing between 19 pmol/g and 47 pmol/g for 
HbAA and between 17 pmol/g and 49 pmol/g 
for HbGA. These differences in mean and 
median levels across different studies may be 
explained by differences in the demographics 
of the populations, differences in analytical 
methods used in these studies, and different 
acrylamide exposures in the different study 
populations. One recent study, investigating 
acrylamide exposure in groups of adults 41–60 
years of age from nine European countries 
and using the same analytical method, found 
median levels among nonsmoking groups 
ranging between 35 pmol/g and 65 pmol/g 
for HbAA and 27 pmol/g and 58 pmol/g for 
HbGA, with the Dutch and British groups 
having the highest median levels (Vesper et al. 
2008). The median HbAA and HbGA levels 
of the comparable age group in this study are 
similar to those found in the Dutch group 
(HbAA: 48.6 pmol/g hemoglobin; HbGA: 
49.6 pmol/g hemoglobin). 
Several investigations have attempted to 
compute a daily intake of acrylamide from 
measured levels of hemoglobin adducts 
(Fennell et al. 2005). In general, these are 
roughly comparable with intakes based on 
dietary estimates (Dybing et al. 2005; FDA 
2006; Mucci and Wilson 2008; Svensson et al. 
2003; World Health Organization 2002). 
Using the computation method of Fennell 
et al. (2005), our adduct data predict a non­
smoking overall population mean intake of 
0.8 µg/kg body weight/day, which is broadly 
similar to some of these other estimates. Our 
findings indicate that secondhand smoke can 
increase HbAA and HbGA levels. Therefore, 
exposure from food may not be the only rel­
evant exposure source in nonsmokers. Some 
limitations are inherent in these types of cal­
culations, including using high­dose acute 
kinetic studies to compute low­dose chronic 
exposure estimates and difficulty in accurately 
accounting for additional (nonadduct) and 
variable pathways of acrylamide metabolism 
and elimination. Although such estimates pro­
vide an approximate magnitude of acrylamide 
exposure, further studies are needed to assess 
the applicability of this model for chronic 
exposures and for estimating subtle differences 
between subpopulations or exposure sources. 
Because acrylamide mutagenicity depends 
on its conversion to glycidamide, it is of inter­
est to determine HbGA levels and to assess 
the relationship between HbAA and HbGA. 
Therefore, we applied a multiple regression 
analysis to predict HbGA levels based on 
HbAA levels, cotinine, sex, and BSA. A 10% 
increase in HbAA levels was associated with an 
HbGA increase ranging between 7.55% and 
9.65% for different population subgroups. 
This increase was similar for smokers and 
nonsmokers. Because of the high intersub­
ject variability in acrylamide metabolism, this 
relationship is applicable only for population 
groups and cannot be applied to individuals. 
The reasons for negative associations 
between BSA and HbAA levels in nonsmok­
ers are not fully understood. Reported asso­
ciations between body mass index and HbAA 
have been inconsistent (Vesper et al. 2008; 
Wilson et al. 2008). On the basis of obser­
vations in animal studies, Osterman­Golkar 
et al. (2003) suggested that increased body 
mass leads to an increase in blood volume 
and the amount of hemoglobin available for 
adduct formation, and thus to a dilution 
of the adducts at similar intake doses. This 
dilution effect also affects serum cotinine lev­
els, complicating further assessments of the 
impact of smoking on HbAA levels, as shown 
in our model for smokers, where increased 
BSA levels tend to attenuate the effect of 
serum cotinine on HbAA. 
The study population is representative of 
U.S. noninstitutionalized individuals, and the 
study results may not be applicable to institu­
tionalized individuals or to other countries. A 
large number of statistical comparisons have 
been made in the analysis of the data, and some 
findings may be the result of random chance. 
The point estimates of biomarker exposure are 
estimates of the various subpopulation exposures 
to acrylamide and not estimates of individual­
ized exposures or specific exposure sources. 
Conclusion
We have characterized U.S. population blood 
acrylamide and glycidamide adduct levels. Sex, 
age, and race/ethnicity do not strongly predict 
adduct levels, suggesting that the large variabil­
ity in adduct levels among nonsmoking indi­
viduals is likely a result of individual intake of 
acrylamide from food and probably, to a lesser 
extent, of exposure to secondhand smoke. 
Dietary, metabolic, or other factors such as 
alcohol intake were not examined in this data 
set. Knowledge of all factors that affect the 
formation of glycidamide, as described in this 
study, will be important with respect to esti­
mating risk from this known carcinogen.
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